{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:53:38Z","timestamp":1765828418531},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,17]]},"DOI":"10.7759\/cureus.64766","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:07:32Z","timestamp":1721261252000},"source":"Crossref","is-referenced-by-count":2,"title":["The Role of Alpha-Synuclein and Tubulin-Associated Unit (Tau) Proteins in the Diagnosis, Prognosis, and Treatment of Parkinson\u2019s Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Yi Mon","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devendar","family":"Banoth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Hassaan","family":"Wali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khava","family":"Bekova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simhachalam","family":"Gurugubelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11065-015-9307-8","article-title":"Do CSF biomarkers predict progression to cognitive impairment in Parkinson\u2019s disease patients? A systematic review","volume":"25","author":"Leaver K","year":"2015","unstructured":"Leaver K, Poston KL. Do CSF biomarkers predict progression to cognitive impairment in Parkinson\u2019s disease patients? A systematic review. Neuropsychol Rev. 2015, 25:411-23. 10.1007\/s11065-015-9307-8","journal-title":"Neuropsychol Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200344","article-title":"Proteinopathy and longitudinal cognitive decline in Parkinson disease","volume":"99","author":"Myers PS","year":"2022","unstructured":"Myers PS, O'Donnell JL, Jackson JJ, et al.. Proteinopathy and longitudinal cognitive decline in Parkinson disease. Neurology. 2022, 99:66-76. 10.1212\/WNL.0000000000200344","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94345-8","article-title":"Temporal trajectory of biofluid markers in Parkinson's disease","volume":"11","author":"Baek MS","year":"2021","unstructured":"Baek MS, Lee MJ, Kim HK, Lyoo CH. Temporal trajectory of biofluid markers in Parkinson's disease. Sci Rep. 2021, 11:14820. 10.1038\/s41598-021-94345-8","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.3861","article-title":"Association of cerebrospinal fluid \u03b2-amyloid 1-42, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease","volume":"70","author":"Kang JH","year":"2013","unstructured":"Kang JH, Irwin DJ, Chen-Plotkin AS, et al.. Association of cerebrospinal fluid \u03b2-amyloid 1-42, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013, 70:1277-87. 10.1001\/jamaneurol.2013.3861","journal-title":"JAMA Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall S","year":"2015","unstructured":"Hall S, Surova Y, \u00d6hrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology. 2015, 84:57-63. 10.1212\/WNL.0000000000001098","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26578","article-title":"Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson\u2019s disease","volume":"31","author":"Hall S","year":"2016","unstructured":"Hall S, Surova Y, \u00d6hrfelt A, Blennow K, Zetterberg H, Hansson O. Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson\u2019s disease. Mov Disord. 2016, 31:898-905. 10.1002\/mds.26578","journal-title":"Mov Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson's disease and dementia with Lewy bodies","volume":"6","author":"Pagan F","year":"2016","unstructured":"Pagan F, Hebron M, Valadez EH, et al.. Nilotinib effects in Parkinson's disease and dementia with Lewy bodies. J Parkinsons Dis. 2016, 6:503-17. 10.3233\/JPD-160867","journal-title":"J Parkinsons Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108843","article-title":"Progress of immunotherapy of anti-\u03b1-synuclein in Parkinson's disease","volume":"115","author":"Wang Z","year":"2019","unstructured":"Wang Z, Gao G, Duan C, Yang H. Progress of immunotherapy of anti-\u03b1-synuclein in Parkinson's disease. Biomed Pharmacother. 2019, 115:108843. 10.1016\/j.biopha.2019.108843","journal-title":"Biomed Pharmacother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234348.s002","article-title":"Newcastle-Ottawa Scale adapted for cross-sectional studies","volume":"15","author":"Abesig J","year":"2020","unstructured":"Abesig J, Chen Y, Wang H, et al.. Newcastle-Ottawa Scale adapted for cross-sectional studies. PLoS One. 2020, 15:e0234348. 10.1371\/journal.pone.0234348.s002","journal-title":"PLoS One"},{"key":"ref12","article-title":"Newcastle-Ottawa Scale Coding Manual for Cohort Studies","author":"Gierisch JM","year":"2014","unstructured":"Gierisch JM, Beadles C, Shapiro A, et al.. Newcastle-Ottawa Scale Coding Manual for Cohort Studies. Department of Veterans Affairs (US), Washington (DC); 2014."},{"key":"ref13","unstructured":"A revised tool to assess risk of bias in randomized trials (RoB 2). (2019). Accessed. November 17, 2023: https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-150682","article-title":"Associations between cerebrospinal fluid biomarkers and cognition in early untreated Parkinson\u2019s disease","volume":"5","author":"Skogseth RE","year":"2015","unstructured":"Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, Aarsland D. Associations between cerebrospinal fluid biomarkers and cognition in early untreated Parkinson\u2019s disease. J Parkinsons Dis. 2015, 5:783-92. 10.3233\/JPD-150682","journal-title":"J Parkinsons Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial","volume":"77","author":"Pagan FL","year":"2020","unstructured":"Pagan FL, Hebron ML, Wilmarth B, et al.. Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 2020, 77:309-17. 10.1001\/jamaneurol.2019.4200","journal-title":"JAMA Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/199298-the-role-of-alpha-synuclein-and-tubulin-associated-unit-tau-proteins-in-the-diagnosis-prognosis-and-treatment-of-parkinsons-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:07:35Z","timestamp":1721261255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/199298-the-role-of-alpha-synuclein-and-tubulin-associated-unit-tau-proteins-in-the-diagnosis-prognosis-and-treatment-of-parkinsons-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.64766","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,17]]}}}